p53参与代谢调控的研究进展

doi:10.13560/j.cnki.biotech.bull.1985.2016.11.007

摘要/Abstract

摘要： p53作为肿瘤抑制因子,其不仅参与遗传毒性应激调节,而且在代谢平衡调控中也发挥重要作用。当机体或细胞处于不同生理逆境时,活化的p53通过参与糖代谢、脂肪酸代谢、ROS水平等相关调节信号通路影响各种代谢途径,进而通过诱导细胞周期阻滞、修复、衰老或凋亡的发生,最终调控机体或细胞产生代谢应激。总结了近年来p53途径的相关报道,对p53与癌症、代谢综合证的关系进行了阐述,以期为进一步理解p53参与的代谢调控提供参考。

关键词: p53, 代谢应激, 能量代谢, 代谢调控

Abstract: As a tumor suppressor,p53 not only is involved in the stress regulation of genetic toxicity,but also plays an important role in the regulation of metabolic balance. When the cells are in different physiological stresses,the activated p53 will affect various metabolic pathways by participating in the regulations of glucose metabolism,fatty acid metabolism,and ROS level. Consequently,the metabolic stress was generated by firstly inducing the occurrence of cell cycle arrest,repair,senescence or apoptosis and finally regulating the organisms and cells. This review summarized the current advances of p53 pathxxray, and discussed the role that p53 played in cancer and metabolic syndrome, which might benefit the study of p53 involved in metabolic regulation.

Key words: p53, metabolic stress, energy metabolism, metabolic regulation

陈珂, 丁艳平, 王建林, 邵宝平. p53参与代谢调控的研究进展[J]. 生物技术通报, 2016, 32(11): 52-58.

CHEN Ke, DING Yan-ping, WANG Jian-lin, SHAO Bao-ping. Research Progress on p53-involved Metabolic Regulation[J]. Biotechnology Bulletin, 2016, 32(11): 52-58.

参考文献

[1] Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours[J]. Nature, 1992, 356（6366）：215-221.
[2] Horn HF, Vousden KH. Coping with stress：multiple ways to activate p53[J]. Oncogene, 2007, 26（9）：1306-1316.
[3] Jones RG, Plas DR, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint[J]. Mol Cell, 2005, 18（3）：283-293.
[4] Maddocks OD, Berkers CR, Mason SM, et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells[J]. Nature, 2013, 493（7433）：542-546.
[5] Zoncu R, Efeyan A, Sabatini DM. mTOR：from growth signal integration to cancer, diabetes and ageing[J]. Nat Rev Mol Cell Biol, 2011, 12（1）：21-35.
[6] Laplante M, Sabatini DM. mTOR signaling at a glance[J]. J Cell Sci, 2009, 122（Pt 20）：3589-3594.
[7] 郑鹏生, 冀静. mTOR信号通路与肿瘤的研究进展[J]. 西安交通大学学报：医学版, 2010, 31（1）：1-9.
[8] Howell JJ, Manning BD. mTOR couples cellular nutrient sensing to organismal metabolic homeostasis[J]. Trends Endocrinol Metab, 2011, 22（3）：94-102.
[9] Laplante M, Sabatini DM. mTOR signaling in growth control and disease[J]. Cell, 2012, 149（2）：274-293.
[10] Huang K, Fingar DC. Growing knowledge of the mTOR signaling network[J]. Semin Cell Dev Biol, 2014, 36：79-90.
[11] Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress[J]. Mol Cell, 2010, 40（2）：310-322.
[12] Cam M, Bid HK, Xiao L, et al. p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1（mTORC1）signaling through two independent parallel pathways in the presence of DNA damage[J]. J Biol Chem, 2014, 289（7）：4083-4094.
[13] Agarwal S, Bell CM, Taylor SM, et al. p53 Deletion or hot-spot mut-ations enhance mTORC1 activity by altering lysosomal dynamics of TSC2 and Rheb[J]. Mol Cancer Res, 2015, 1：66-77.
[14] Imamura K, Ogura T, Kishimoto A, et al. Cell cycle regulation via p53 phosphorylation by a 5’-AMP activated protein kinase activa-tor, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line[J]. Biochem Biophys Res Commun, 2001, 2：562-567.
[15] Lee CW, Wong LL, Tse EY, et al. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells[J]. Cancer Res, 2012, 72（17）：4394-4404.
[16] Mungamuri SK, Yang X, Thor AD, et al. Survival signaling by Notch1：mammalian target of rapamycin（mTOR）-dependent inhibition of p53[J]. Cancer Res, 2006, 66（9）：4715-4724.
[17] Astle MV, Hannan KM, Ng PY, et al. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage：implications for targeting mTOR during malignancy[J]. Oncogene, 2012, 31（15）：1949-1962.
[18] Lee CH, Inoki K, Karbowniczek M, et al. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53[J]. Embo J, 2007, 23：4812-4823.
[19] Kruiswijk F, Labuschagne CF, Vousden KH. p53 in survival, death and metabolic health：a lifeguard with a licence to kill[J]. Nat Rev Mol Cell Biol, 2015, 16（7）：393-405.
[20] Li H, Jogl G. Structural and biochemical studies of TIGAR（TP53-induced glycolysis and apoptosis regulator）[J]. J Biol Chem, 2009, 284（3）：1748-1754.
[21] Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis[J]. Cell, 2006, 126（1）：107-120.
[22] Kondoh H, Lleonart ME, Gil J, et al. Glycolytic enzymes can modulate cellular life span[J]. Cancer Res, 2005, 65（1）：177-185.
[23] Contractor T, Harris CR. p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2[J]. Cancer Res, 2012, 72（2）：560-567.
[24] Wang L, Xiong H, Wu F, et al. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth[J]. Cell Rep, 2014, 8（5）：1461-1474.
[25] Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression[J]. Cancer Res, 2004, 7：2627-2633.
[26] Singh SK, Chen NM, Hessmann E, et al. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity[J]. Embo J, 2015, 34（24）：2985-3037.
[27] Kawauchi K, Araki K, Tobiume K, et al. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation[J]. Nat Cell Biol, 2008, 10（5）：611-618.
[28] Boidot R, Vegran F, Meulle A, et al. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors[J]. Cancer Res, 2012, 4：939-948.
[29] Bensaad K, Cheung EC, Vousden KH. Modulation of intracellular ROS levels by TIGAR controls autophagy[J]. Embo J, 2009, 28（19）：3015-3026.
[30] Wanka C, Steinbach JP, Rieger J. Tp53-induced glycolysis and apoptosis regulator（TIGAR）protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis[J]. J Biol Chem, 2012, 287（40）：33436-33446.
[31] Cheung EC, Ludwig RL, Vousden KH. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death[J]. Proc Natl Acad Sci USA, 2012, 50：20491-20496.
[32] Jiang P, Du W, Wang X, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase[J]. Nat Cell Biol, 2011, 13（3）：310-316.
[33] Siegl C, Prusty BK, Karunakaran K, et al. Tumor suppressor p53 alters host cell metabolism to limit Chlamydia trachomatis infection[J]. Cell Rep, 2014, 9（3）：918-929.
[34] Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration[J]. Science, 2006, 312（5780）：1650-1653.
[35] Jiang P, Du W, Mancuso A, et al. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence[J]. Nature, 2013, 493（7434）：689-693.
[36] Puzio-Kuter AM. The role of p53 in metabolic regulation[J]. Genes Cancer, 2011, 2（4）：385-391.
[37] Hallenborg P, Feddersen S, Madsen L, et al. The tumor suppressors pRB and p53 as regulators of adipocyte differentiation and function[J]. Expert Opin Ther Targets, 2009, 2：235-246.
[38] Wang X, Zhao X, Gao X, et al. A new role of p53 in regulating lipid metabolism[J]. J Mol Cell Biol, 2013, 5（2）：147-150.
[39] Goldstein I, Rotter V. Regulation of lipid metabolism by p53 - fighting two villains with one sword[J]. Trends Endocrinol Metab, 2012, 23（11）：567-575.
[40] Zaugg K, Yao Y, Reilly PT, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress[J]. Genes Dev, 2011, 25（10）：1041-1051.
[41] Ide T, Brown-Endres L, Chu K, et al. GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress[J]. Mol Cell, 2009, 36（3）：379-392.
[42] Liu Y, He Y, Jin A, et al. Ribosomal protein-Mdm2-p53 pathway coordinates nutrient stress with lipid metabolism by regulating MCD and promoting fatty acid oxidation[J]. Proc Natl Acad Sci USA, 2014, 111（23）：E2414-22.
[43] Kim J, Nakasaki M, Todorova D, et al. p53 Induces skin aging by depleting Blimp1+ sebaceous gland cells[J]. Cell Death Dis, 2014, 27（5）：87-97.
[44] Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling[J]. Cell, 2008, 134（3）：451-460.
[45] Yoon KA, Nakamura Y, Arakawa H. Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses[J]. J Hum Genet, 2004, 49（3）：134-140.
[46] Ambs S, Ogunfusika MO, Merriam WG, et al. Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice[J]. Proc Natl Acad Sci USA, 1998, 95（15）：8823-8828.
[47] Subbaramaiah K, Michaluart P, Chung WJ, et al. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells[J]. Ann N Y Acad Sci, 1999, 889：214-223.
[48] Zhuang J, Ma W, Lago CU, et al. Metabolic regulation of oxygen and redox homeostasis by p53：lessons from evolutionary biology?[J]. Free Radic Biol Med, 2012, 53（6）：1279-1285.
[49] Rivera A, Maxwell SA. The p53-induced gene-6（proline oxidase）mediates apoptosis through a calcineurin-dependent pathway[J]. J Biol Chem, 2005, 280（32）：29346-29354.
[50] Jiang L, Hickman JH, Wang SJ, et al. Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses[J]. Cell Cycle, 2015, 14（18）：2881-2885.
[51] Italiano D, Lena AM, Melino G, et al. Identification of NCF2/p67phox as a novel p53 target gene[J]. Cell Cycle, 2012, 11（24）：4589-4596.
[52] Kang MY, Kim HB, Piao C, et al. The critical role of catalase in prooxidant and antioxidant function of p53[J]. Cell Death Differ, 2013, 20（1）：117-129.
[53] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect：the metabolic requirements of cell proliferation[J]. Science, 2009, 324（5930）：1029-1033.
[54] Ward PS, Thompson CB. Metabolic reprogramming：a cancer hallmark even warburg did not anticipate[J]. Cancer Cell, 2012, 21（3）：297-308.
[55] Liu J, Zhang C, Hu W, et al. Tumor suppressor p53 and its mutants in cancer metabolism[J]. Cancer Lett, 2015, 356（2 Pt A）：197-203.
[56] Li T, Kon N, Jiang L, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence[J]. Cell, 2012, 149（6）：1269-1283.
[57] Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein[J]. Trends Cell Biol, 2010, 20（7）：427-434.
[58] Hasty P, Sharp ZD, Curiel TJ, et al. mTORC1 and p53：clash of the gods?[J]. Cell Cycle, 2013, 12（1）：20-25.
[59] Akeno N, Miller AL, Ma X, et al. p53 suppresses carcinoma progression by inhibiting mTOR pathway activation[J]. Oncogene, 2014, 27（10）：589-599.
[60] Pena-Rico MA, Calvo-Vidal MN, Villalonga-Planells R, et al. TP53 induced glycolysis and apoptosis regulator（TIGAR）knockdown results in radiosensitization of glioma cells[J]. Radiother Oncol, 2011, 101（1）：132-139.
[61] Singh RD, Patel KR, Patel PS. p53 mutation spectrum and its role in prognosis of oral cancer patients：A study from Gujarat, West India[J]. Mutat Res, 2015, 783（2016）：15-26.
[62] Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers[J]. Science, 2006, 314（5797）：268-274.
[63] 缪明永. P53突变或缺失与肿瘤代谢重编程[J]. 肿瘤代谢与营养电子杂志, 2014, 1（2）：26-30.
[64] Oren M, Rotter V. Mutant p53 gain-of-function in cancer[J]. Cold Spring Harb Perspect Biol, 2010, 2（2）：a001107.
[65] Muller PA, Vousden KH. p53 mutations in cancer[J]. Nat Cell Biol, 2013, 15（1）：2-8.
[66] Freed-Pastor WA, Prives C. Mutant p53：one name, many proteins[J]. Genes Dev, 2012, 26（12）：1268-1286.
[67] Yahagi N, Shimano H, Matsuzaka T, et al. p53 Activation in adipocytes of obese mice[J]. J Biol Chem, 2003, 278（28）：25395-25400.
[68] Derdak Z, Villegas KA, Harb R, et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease[J]. J Hepatol, 2013, 58（4）：785-791.
[69] Zhang X, Duan W, Lee WP, et al. Overexpression of p53 improves blood glucose control in an insulin resistant diabetic mouse model[J]. Pancreas, 2016, 45（7）：1010-1017.
[70] Kung CP, Leu JI, Basu S, et al. The P72R polymorphism of p53 predisposes to obesity and metabolic dysfunction[J]. Cell Rep, 2016, 14（10）：2413-2425.
[71] Porteiro B, Diaz-Ruiz A, Martinez G, et al. Ghrelin requires p53 to stimulate lipid storage in fat and liver[J]. Endocrinology, 2013, 154（10）：3671-3679.